Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.
Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.
